Atea Pharmaceuticals (NASDAQ:AVIR) Announces Earnings Results, Beats Estimates By $0.03 EPS

Posted by Brian Himes on May 12th, 2026

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.03, FiscalAI reports.

Atea Pharmaceuticals Stock Performance

NASDAQ:AVIR traded up $0.09 during trading hours on Tuesday, reaching $5.50. The company’s stock had a trading volume of 308,800 shares, compared to its average volume of 466,422. The company has a market capitalization of $440.17 million, a P/E ratio of -2.84 and a beta of 0.38. Atea Pharmaceuticals has a 12 month low of $2.45 and a 12 month high of $6.45. The stock has a 50 day moving average price of $5.61 and a two-hundred day moving average price of $4.28.

Hedge Funds Weigh In On Atea Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AVIR. JPMorgan Chase & Co. grew its holdings in Atea Pharmaceuticals by 118.6% in the fourth quarter. JPMorgan Chase & Co. now owns 1,348,294 shares of the company’s stock worth $4,813,000 after purchasing an additional 731,443 shares during the last quarter. Millennium Management LLC grew its holdings in Atea Pharmaceuticals by 179.2% in the third quarter. Millennium Management LLC now owns 487,223 shares of the company’s stock worth $1,413,000 after purchasing an additional 312,733 shares during the last quarter. Bank of America Corp DE grew its holdings in Atea Pharmaceuticals by 185.8% in the third quarter. Bank of America Corp DE now owns 313,644 shares of the company’s stock worth $910,000 after purchasing an additional 203,905 shares during the last quarter. Opaleye Management Inc. purchased a new position in Atea Pharmaceuticals in the fourth quarter worth $642,000. Finally, Goldman Sachs Group Inc. grew its holdings in Atea Pharmaceuticals by 38.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 472,522 shares of the company’s stock worth $1,687,000 after purchasing an additional 132,382 shares during the last quarter. 86.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Check Out Our Latest Analysis on Atea Pharmaceuticals

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.